Monopar to Present at the H.C. Wainwright BioConnect Conference

On January 7, 2022 Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, reported that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference (Press release, Monopar Therapeutics, JAN 7, 2022, https://ir.monopartx.com/news/detail/48/monopar-to-present-at-the-h-c-wainwright-bioconnect-conference [SID1234598417]). The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Date: Monday, January 10, 2022

Time: 7:00am ET

Location: Virtual

View Source